Citations

Clear

4847 citation(s) found for "Tu, Eric".

Dysanapsis Genetic Risk Predicts Lung Function Across the Lifespan
Debban, Catherine L., Ambalavanan, Amirthagowri , Ghosh, Auyon , Buschur, Kristina L., Ma, Yanlin , George, Elizabeth , Pistenmaa, Carrie L. , Bertoni, Alain G. , Oelsner, Elizabeth C. , Moraes, Theo J. , Jacobs, David R. , Christenson, Stephanie A. , Bhatt, Surya P. , Simons, Elinor , Turvey, Stuart E. , Vameghestahbanati, Motahareh , Bourbeau, Jean , Tan, Wan C. , Gabriel, Stacey , Gupta, Namrata , Woodruff, Prescott G. , Ortega, Victor E. , Bleecker, Eugene R. , Meyers, Deborah A. , Hoffman, Eric A. , Barr, R. Graham, Duan, Qing , Smith, Benjamin M. , George, Elizabeth , Bertoni, Alain G , Oelsner, Elizabeth C , Michos, Erin D , Moraes, Theo J , Bhatt, Surya P , Turvey, Stuart E , Engert, James C , Kirby, Miranda , Tan, Wan C , Woodruff, Prescott G , Subbarao, Padmaja , Rich, Stephen S , Hoffman, Eric A , Cho, Michael H , Bossé, Yohan , Duan, Qingling , Manichaikul, Ani W , Ghosh, Auyon J , Jacobs, David R , Christenson, Stephanie A , Ambalavanan, Amirthagowri , Li, Zhonglin , Michos, Erin D. , Kaner, Robert J. , Rich, Stephen S. , Cho, Michael H. , Bossé, Yohan , Manichaikul, Ani

Mayo Clinic

American Journal of Respiratory and Critical Care Medicine | June 27, 2024 | Volume: 210 | Issue: 12 | Pages: 1421-1431

10.1164/rccm.202401-0011oc | PMID 38935874 Get It

Abstract Rationale Dysanapsis refers to a mismatch between airway tree caliber and lung size arising early in life. Dysanapsis assessed by computed tomography (CT) is evident by early adulthood and associated with chronic obstructive pulmonary disease (COPD) risk later in life. Objectives By examining the genetic factors associated with CT-assessed dysanapsis, we aimed to elucidate its molecular underpinnings and physiological significance across the lifespan. Methods We performed a genome-wide association study of CT-assessed dysanapsis in 11,951 adults, including individuals from two population-based and two COPD-enriched studies. We applied colocalization analysis to integrate genome-wide association study and gene expression data from whole blood and lung. Genetic variants associated with dysanapsis were combined into a genetic risk score that was applied to examine association with lung function in children from a population-based birth cohort (n = 1,278) and adults from the UKBiobank (n = 369,157). Measurements and Main Results CT-assessed dysanapsis was associated with genetic variants from 21 independent signals in 19 gene regions, implicating HHIP (hedgehog interacting protein), DSP, and NPNT as potential molecular targets based on colocalization of their expression. A higher dysanapsis genetic risk score was associated with obstructive spirometry among 5-year-old children and among adults in the fifth, sixth, and seventh decades of life. Conclusions CT-assessed dysanapsis is associated with variation in genes previously implicated in lung development, and dysanapsis genetic risk is associated with obstructive lung function from early life through older adulthood. Dysanapsis may represent an endophenotype link between the genetic variations associated with lung function and COPD.
Paradoxical thinning of the diaphragm on ultrasound is a risk factor for requiring non‐invasive ventilation in patients with neuromuscular diaphragmatic dysfunction
Boon, Andrea J. , Meiling, James B. , Luetmer, Marianne T. , Sorenson, Eric J. , Harper, C. Michel , Beecher, Grayson , Klein, Christopher J , Beecher, Grayson , Meiling, James B , Klein, Christopher J.

Mayo Clinic

Muscle & Nerve | June 27, 2024 | Volume: 70 | Issue: 3 | Pages: 352-359

10.1002/mus.28194 | PMID 38935447 Get It

Abstract Introduction/Aims Point‐of‐care ultrasound of the diaphragm is highly sensitive and specific in the detection of neuromuscular diaphragmatic dysfunction. In some patients with neuromuscular diaphragmatic dysfunction, paradoxical thinning of the diaphragm during inspiration is observed on ultrasound; however, its frequency, electrodiagnostic associations, and prognostic significance remain uncertain. Methods Medical records of patients presenting to two electrodiagnostic laboratories (Mayo Clinic, Rochester, Minnesota and University of Alberta, Edmonton, Alberta) from January 1, 2022 to December 31, 2022, for evaluation of suspected neuromuscular respiratory failure, were reviewed. Results 214 patients were referred and 19 patients excluded due to incomplete information. Of 195 patients (384 hemidiaphragms), 104 had phrenic neuropathy, 12 had myopathy, and 79 had no evidence of neuromuscular disease affecting the diaphragm. Paradoxical thinning occurred in 31 (27%) patients with neuromuscular diaphragmatic dysfunction and was unilateral in 30, the majority (83%) having normal contralateral ultrasound. Phrenic nerve conduction studies and diaphragm electromyography results did not distinguish patients with paradoxical thinning versus without. Most patients (71%) with paradoxical thinning required non‐invasive ventilation (NIV), including 16 with unilateral paradoxical thinning. Paradoxical thinning and BMI ≥30 kg/m 2 were risk factors for requiring NIV in multivariable logistic regression analysis, with odds ratios of 2.887 (95% CI:1.166, 7.151) and 2.561 (95% CI: 1.186, 5.532), respectively. Discussion Paradoxical thinning of the diaphragm occurs in patients with prominent neuromuscular diaphragmatic dysfunction, most commonly from phrenic neuropathy, and is a significant risk factor for requiring NIV. Unilateral paradoxical thinning is sufficient for needing NIV. BMI ≥30 kg/m 2 additionally increases risk of requiring NIV in patients with neuromuscular diaphragmatic dysfunction.
Revised criteria for diagnosis and staging of Alzheimer's disease: Alzheimer's Association Workgroup
Jack, Clifford R. , Andrews, J. Scott , Beach, Thomas G. , Buracchio, Teresa , Dunn, Billy , Graf, Ana, Ho, Carole , Jagust, William J. , Okonkwo, Ozioma C. , Siemers, Eric , Snyder, Heather M. , Carrillo, Marı́a C., Carrillo, María C. , Jack, Clifford R , Hansson, Oskar , McDade, Eric , Molinuevo, José Luís , Pani, Luca , Rafii, Michael S. , Scheltens, Philip , Sperling, Reisa Anne , Teunissen, Charlotte E.

Mayo Clinic

Alzheimer's & Dementia | June 27, 2024 | Volume: 20 | Issue: 8 | Pages: 5143-5169

10.1002/alz.13859 | PMID 38934362 Get It

Abstract The National Institute on Aging and the Alzheimer's Association convened three separate work groups in 2011 and single work groups in 2012 and 2018 to create recommendations for the diagnosis and characterization of Alzheimer's disease (AD). The present document updates the 2018 research framework in response to several recent developments. Defining diseases biologically, rather than based on syndromic presentation, has long been standard in many areas of medicine (e.g., oncology), and is becoming a unifying concept common to all neurodegenerative diseases, not just AD. The present document is consistent with this principle. Our intent is to present objective criteria for diagnosis and staging AD, incorporating recent advances in biomarkers, to serve as a bridge between research and clinical care. These criteria are not intended to provide step‐by‐step clinical practice guidelines for clinical workflow or specific treatment protocols, but rather serve as general principles to inform diagnosis and staging of AD that reflect current science. Highlights We define Alzheimer's disease (AD) to be a biological process that begins with the appearance of AD neuropathologic change (ADNPC) while people are asymptomatic. Progression of the neuropathologic burden leads to the later appearance and progression of clinical symptoms. Early‐changing Core 1 biomarkers (amyloid positron emission tomography [PET], approved cerebrospinal fluid biomarkers, and accurate plasma biomarkers [especially phosphorylated tau 217]) map onto either the amyloid beta or AD tauopathy pathway; however, these reflect the presence of ADNPC more generally (i.e., both neuritic plaques and tangles). An abnormal Core 1 biomarker result is sufficient to establish a diagnosis of AD and to inform clinical decision making throughout the disease continuum. Later‐changing Core 2 biomarkers (biofluid and tau PET) can provide prognostic information, and when abnormal, will increase confidence that AD is contributing to symptoms. An integrated biological and clinical staging scheme is described that accommodates the fact that common copathologies, cognitive reserve, and resistance may modify relationships between clinical and biological AD stages.
Combination Targeted Therapy with Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers
French, Jena D. , Haugen, Bryan R. , Worden, Francis P. , Bowles, Daniel W. , Gianoukakis, Andrew G. , Konda, Bhavana , Dadu, Ramona , Sherman, Eric J. , McCue, Shaylene , Foster, Nathan R. , Farias, Ticiana D.J. , Norman, Paul J. , Wirth, Lori J. , Nikiforov, Yuri , Farias, Ticiana D J , Norman, Paul J , Wirth, Lori J , Bowles, Daniel W , Worden, Frank , Nikiforov, Yuri E.

Mayo Clinic

Clinical Cancer Research | June 26, 2024 | Volume: 30 | Issue: 17 | Pages: 3757-3767

10.1158/1078-0432.ccr-23-3417 | PMID 38922338 Get It

Abstract Purpose: Lenvatinib, a potent multikinase inhibitor, improves progression-free survival (PFS) in patients with radioiodine (RAI)-refractory differentiated thyroid cancer; however, most patients experience disease progression, warranting further therapy. We evaluated the efficacy and safety of lenvatinib plus pembrolizumab in these patients. Patients and Methods: We enrolled patients with progressive, RAI-refractory differentiated thyroid cancer who were either naïve to multikinase inhibitors (cohort 1) or who had progressed on lenvatinib (cohort 2). Patients received oral lenvatinib daily (cohort 1, 20 mg; cohort 2, dose at progression) and intravenous pembrolizumab (200 mg) every 21 days. Results: In cohorts 1 and 2, 30 and 27 patients were enrolled, respectively. Adverse events were consistent with those observed in other cancers. In cohort 1, the confirmed overall response rate was 65.5%. There were no complete responses (primary endpoint). The 12- and 18-month PFS were 72.0% and 58.0%, respectively, and the median PFS was 26.8 months. In cohort 2, the confirmed overall response rate was 16% (primary endpoint), and the median PFS was 10.0 months (95% confidence interval, 7.0–17.9 months). Tumor histology, driver mutations, and immune-related biomarkers, including PD-L1 expression, thyroid-specific antibody levels, and CD8+ T-cell tumor infiltrate, did not correlate with response to therapy. Increased baseline peripheral blood monocytes and neutrophil to lymphocyte ratio were associated with a worse PFS in cohort 1. Conclusions: Lenvatinib plus pembrolizumab may enhance the durability of lenvatinib monotherapy in lenvatinib-naïve patients. Furthermore, the addition of pembrolizumab may be a viable salvage therapy for patients who have progressed on lenvatinib.
Charting the course: natural language processing unveils regional anesthesia procedures in clinical records – an infographic
D’Souza, Ryan S. , Graham, Laura A. , D'Souza, Ryan S , Schwenk, Eric S.

Mayo Clinic

Regional Anesthesia & Pain Medicine | June 26, 2024 | Volume: 50 | Issue: 8 | Pages: 685-685

10.1136/rapm-2024-105720 | PMID 38925713 Get It

Central Retinal Artery Occlusion Associated with Takayasu Arteritis
Mumtaz, Sehreen , Wilson, Claire , Eggenberger, Eric , Berianu, Florentina , Abril, Andy , Vibhute, Prasanna , Eggenberger, Eric R, Mumtaz, Sehreen

Mayo Clinic

Diagnostics | June 24, 2024 | Volume: 14 | Issue: 13 | Pages: 1329

10.3390/diagnostics14131329 | PMID 39001220 Get It

Takayasu arteritis is a chronic inflammatory vasculitis with granulomatous panarteritis particularly impacting large vessels including the aorta and its branches, especially the subclavian arteries, with clinical manifestation dependent on the involved artery. Sequelae of the active disease vary, including stenosis, occlusions, or aneurysmal dilatations of the large vessels. The prevalence of Takayasu arteritis is higher in the Asian population and in Japan, but quite low in the United States, varying from 0.9–8.4 per million people. Ocular manifestations are rare and lead to a delay in diagnosis and appropriate treatment. Ocular manifestations include Takayasu retinopathy, anterior ischemic optic neuropathy (AION), retinal artery occlusion (RAO) and retinal vein occlusion (RVO). We present two cases in which central retinal artery occlusion (CRAO) was associated with Takayasu arteritis. CRAO is an ophthalmic emergency with an incidence of 1.9 per 100,000 person years in the United States; only 5% of cases are arteritic, which can be observed with inflammatory vasculitides secondary to the formation of immune deposits.
Utility of methylated DNA markers for the diagnosis of malignant biliary strictures
Cooley, Matthew A. , Schneider, Amber, Fritcher, Emily G. Barr , Milosevic, Dragana , Levy, Michael J. , Bridgeman, Amber R. , Martin, John A. , Petersen, Bret T. , Dayyeh, Barham K. Abu , Law, Ryan , Garimella, Vishal, Jenkins, Sarah M. , Yin, Jun, Roberts, Lewis R. , Kipp, Benjamin R. , Ferrándiz‐Pulido, Carla , Schneider, Amber R, Abu Dayyeh, Barham K , Storm, Andrew C , Law, Ryan J, Vargas, Eric J , Roberts, Lewis R , Kipp, Benjamin , Chandrasekhara, Vinay , Barr Fritcher, Emily G , Bridgeman, Amber R , Levy, Michael J. , Storm, Andrew C. , Vargas, Eric J. , Zemla, Tyler , Gores, Gregory J. , Chandrasekhara, Vinay

Mayo Clinic

Hepatology | June 21, 2024 | Volume: 81 | Issue: 2 | Pages: 453-464

10.1097/hep.0000000000000970 | PMID 38905442 Get It

Background and Aims: Early identification of malignant biliary strictures (MBSs) is challenging, with up to 20% classified as indeterminants after preliminary testing and tissue sampling with endoscopic retrograde cholangiopancreatography. We aimed to evaluate the use of methylated DNA markers (MDMs) from biliary brushings to enhance MBS detection in a prospective cohort. Approach: Candidate MDMs were evaluated for their utility in MBS diagnosis through a series of discovery and validation phases. DNA was extracted from biliary brushing samples, quantified, bisulfite-converted, and then subjected to methylation-specific droplet digital polymerase chain reaction. Patients were considered to have no malignancy if the sampling was negative and there was no evidence of malignancy after 1 year or definitive negative surgical histopathology. Results: Fourteen candidate MDMs were evaluated in the discovery phase, with top-performing and new markers evaluated in the technical validation phase. The top 4 MDMs were TWIST1, HOXA1, VSTM2B, and CLEC11A, which individually achieved AUC values of 0.82, 0.81, 0.83, and 0.78, respectively, with sensitivities of 59.4%, 53.1%, 62.5%, and 50.0%, respectively, at high specificities for malignancy of 95.2%–95.3% for the final biologic validation phase. When combined as a panel, the AUC was 0.86, achieving 73.4% sensitivity and 92.9% specificity, which outperformed cytology and fluorescence in situ hybridization (FISH). Conclusions: The selected MDMs demonstrated improved performance characteristics for the detection of MBS compared to cytology and FISH. Therefore, MDMs should be considered viable candidates for inclusion in diagnostic testing algorithms.
Alliance A022101/NRG-GI009: A pragmatic randomized phase III trial evaluating total ablative therapy for patients with limited metastatic colorectal cancer—Evaluating radiation, ablation, and surgery (ERASur).
Gholami, Sepideh , White, Sarah B. , Wu, Christina, Goulet, Christopher C., Jee, Kyung‐Wook , Wright, Chadwick , Yaeger, Rona , Shergill, Ardaman , Hong, Theodore S. , Miller, Eric D. , Hitchcock, Kathryn E. , Shi, Qian , Dixon, Jesse G. , George, Thomas J. , O’Reilly, Eileen M. , Meyerhardt, Jeffrey A. , Romesser, Paul B.

Mayo Clinic

Journal of Clinical Oncology | June 21, 2024 | Volume: 42 | Issue: 16_suppl | Pages: TPS3633-TPS3633

10.1200/jco.2024.42.16_suppl.tps3633 Get It

TPS3633 Background: For patients with oligometastatic colorectal cancer (CRC), aggressive local therapy of isolated metastases, particularly in the liver, has been associated with long-term progression-free and overall survival (OS) primarily based on retrospective evidence. However, in patients with limited metastatic CRC that is deemed inoperable or those with additional disease outside of the liver or lungs, the role of local ablative therapies, including microwave ablation (MWA) and stereotactic body radiation therapy (SBRT), to render patients disease free is less clear. Further, despite the long history of treating oligometastatic CRC with local therapy, which is provider biased and not evidence based, questions remain regarding the benefit of extending the paradigm of metastatic directed therapy to patients with more extensive disease. This trial seeks to use a pragmatic multimodality approach that mirrors the current clinical dilemma. This study is designed to evaluate the safety and efficacy of adding total ablative therapy (TAT) of all sites of disease to standard of care systemic treatment in those with limited metastatic CRC. Methods: A022101/NRG-GI009 is a National Clinical Trials Network randomized phase III study planned to enroll 364 patients with newly diagnosed metastatic CRC (BRAF wild-type, microsatellite stable) with ≤4 sites of metastatic disease on baseline imaging. Liver-only metastatic disease is not permitted, and lesions must be amenable to any combination of surgical resection, MWA, and/or SBRT with SBRT required for at least 1 lesion. Patients receive first-line systemic therapy for 16-26 weeks and are then randomized 1:1, stratified by number of metastatic organ sites (1-2 vs. 3-4), timing of metastatic disease diagnosis (de novo vs. secondary), and presence of metastatic disease outside the liver/lungs in at least 1 site. Patients in Arm 1 will receive TAT consisting of treatment of all metastatic sites with SBRT ± MWA ± surgical resection followed by standard of care systemic therapy. Patients in Arm 2 will continue with standard of care systemic therapy alone. The primary endpoint is OS. Secondary endpoints include event-free survival, treatment-related toxicities, and local recurrence with exploratory biomarker analyses. The study needs 346 evaluable patients combined in the 2 arms to demonstrate an improvement in OS with a hazard ratio of 0.7 to provide 80% power with a one-sided alpha of 5%. The trial utilizes a group sequential design with two interim analyses (25% and 50% of events) for futility. The trial activated in January 2023 and recruitment is ongoing. Support: U10CA180821, U10CA180882; https://acknowledgments.alliancefound.org. U10CA180820 (ECOG-ACRIN); U10CA180868 (NRG); U10CA180888 (SWOG); Clinicaltrials.gov identifier: NCT05673148 Clinical trial information: NCT05673148 .
Riluzole for Degenerative Cervical Myelopathy
Pedro, Karlo M. , Badhiwala, Jetan H. , Ahn, Henry, Shaffrey, Christopher I. , Mummaneni, Praveen V. , Jacobs, W. Bradley , Riew, K. Daniel , Hilibrand, Alan S. , Kim, Kee D. , Fourney, Daryl R. , Santaguida, Carlo , Massicotte, Eric M. , Fehlings, Michael G. , Alvi, Mohammed Ali , Farhadi, H. Francis , Nassr, Ahmad , Arnold, Paul M. , Riew, Kiehyun Daniel , Kelly, Michael P. , Brodke, Darrel Scott , Vaccaro, Alexander R. , Wilson, Jason, Harrop, James Shields , Huang, Peng

Mayo Clinic

JAMA Network Open | June 21, 2024 | Volume: 7 | Issue: 6 | Pages: e2415643

10.1001/jamanetworkopen.2024.15643 | PMID 38904964 Get It

Importance The modified Japanese Orthopaedic Association (mJOA) scale is the most common scale used to represent outcomes of degenerative cervical myelopathy (DCM); however, it lacks consideration for neck pain scores and neglects the multidimensional aspect of recovery after surgery. Objective To use a global statistical approach that incorporates assessments of multiple outcomes to reassess the efficacy of riluzole in patients undergoing spinal surgery for DCM. Design, Setting, and Participants This was a secondary analysis of prespecified secondary end points within the Efficacy of Riluzole in Surgical Treatment for Cervical Spondylotic Myelopathy (CSM-PROTECT) trial, a multicenter, double-blind, phase 3 randomized clinical trial conducted from January 2012 to May 2017. Adult surgical patients with DCM with moderate to severe myelopathy (mJOA scale score of 8-14) were randomized to receive either riluzole or placebo. The present study was conducted from July to December 2023. Intervention Riluzole (50 mg twice daily) or placebo for a total of 6 weeks, including 2 weeks prior to surgery and 4 weeks following surgery. Main Outcomes and Measures The primary outcome measure was a difference in clinical improvement from baseline to 1-year follow-up, assessed using a global statistical test (GST). The 36-Item Short Form Health Survey Physical Component Score (SF-36 PCS), arm and neck pain numeric rating scale (NRS) scores, American Spinal Injury Association (ASIA) motor score, and Nurick grade were combined into a single summary statistic known as the global treatment effect (GTE). Results Overall, 290 patients (riluzole group, 141; placebo group, 149; mean [SD] age, 59 [10.1] years; 161 [56%] male) were included. Riluzole showed a significantly higher probability of global improvement compared with placebo at 1-year follow-up (GTE, 0.08; 95% CI, 0.00-0.16; P = .02). A similar favorable global response was seen at 35 days and 6 months (GTE for both, 0.07; 95% CI, −0.01 to 0.15; P = .04), although the results were not statistically significant. Riluzole-treated patients had at least a 54% likelihood of achieving better outcomes at 1 year compared with the placebo group. The ASIA motor score and neck and arm pain NRS combination at 1 year provided the best-fit parsimonious model for detecting a benefit of riluzole (GTE, 0.11; 95% CI, 0.02-0.16; P = .007). Conclusions and Relevance In this secondary analysis of the CSM-PROTECT trial using a global outcome technique, riluzole was associated with improved clinical outcomes in patients with DCM. The GST offered probability-based results capable of representing diverse outcome scales and should be considered in future studies assessing spine surgery outcomes.
Lipoprotein(a) and long-term in-stent restenosis after percutaneous coronary intervention
Mahmoud, Ahmed , Awad, Kamal , Ali, Nima Baba , Pereyra, Milagros , Scalia, Isabel G. , Allam, Mohamed, Kamel, Moaz, Rmilah, Anan Abu , Chao, Chieh-Ju, Barry, Timothy, Lester, Steven J., Pollak, Peter , Sweeney, John P., Fortuin, David, Arsanjani, Reza , Mahmoud, Ahmed K , Allam, Mohamed N , Kamel, Moaz A, Alsidawi, Said , Pollak, Peter M, Alkhouli, Mohamad A, Lee, Richard W, Fortuin, David F, Arsanjani, Reza , Pereyra, Milagros , Scalia, Isabel G , Awad, Kamal , Farina, Juan M. , Abbas, Mohammed Tiseer , Allam, Mohamed N, Chao, Chieh‐Ju , Alsidawi, Said , Alkhouli, Mohamad , Lee, Kwan , Yang, Eric H. , Lee, Richard

Mayo Clinic

European Journal of Preventive Cardiology | June 20, 2024 | Volume: 31 | Issue: 15 | Pages: 1878-1887

10.1093/eurjpc/zwae212 | PMID 38916491 Get It

Abstract Aims Lipoprotein(a) [Lp(a)] has demonstrated its association with atherosclerosis and myocardial infarction. However, its role in the development of in-stent restenosis (ISR) after percutaneous coronary intervention (PCI) is not clearly established. The aim of this study is to investigate the association between Lp(a) and ISR. Methods and results A retrospective study of adult patients who underwent successful PCI between January 2006 and December 2017 at the three Mayo Clinic sites and had a preprocedural Lp(a) measurement was conducted. Patients were divided into two groups according to the serum Lp(a) concentration [high Lp(a) ≥ 50 mg/dL and low Lp(a) < 50 mg/dL]. Univariable and multivariable analyses were performed to compare risk of ISR between patients with high Lp(a) vs. those with low Lp(a). A total of 1209 patients were included, with mean age 65.9 ± 11.7 years and 71.8% were male. Median follow-up after baseline PCI was 8.8 [interquartile range (IQR) 7.4] years. Restenosis was observed in 162 (13.4%) patients. Median serum levels of Lp(a) were significantly higher in patients affected by ISR vs. non-affected cases: 27 (IQR 73.8) vs. 20 (IQR 57.5) mg/dL, P = 0.008. The rate of ISR was significantly higher among patients with high Lp(a) vs. patients with low Lp(a) values (17.0% vs. 11.6%, P = 0.010). High Lp(a) values were independently associated with ISR events (hazard ratio 1.67, 95% confidence interval 1.18–2.37, P = 0.004), and this association was more prominent after the first year following the PCI. Conclusion Lipoprotein(a) is an independent predictor for long-term ISR and should be considered in the evaluation of patients undergoing PCI.